2,242 results match your criteria Autoimmunity Reviews [Journal]


Thyroid disorders in patients with systemic sclerosis: A systematic review and meta-analysis.

Autoimmun Rev 2019 Apr 5. Epub 2019 Apr 5.

Department of Endocrinology, Shanghai University of Medicine & Health Sciences Affiliated Zhoupu Hospital, No. 1500 Zhouyuan Road, Pudong District, Shanghai 201318, China. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2019.01.003DOI Listing
April 2019
2 Reads

The pipeline of targeted therapies under clinical development for primary Sjögren's syndrome: A systematic review of trials.

Autoimmun Rev 2019 Apr 6. Epub 2019 Apr 6.

Service de rhumatologie, Hôpitaux Universitaires de Strasbourg, F-67000 Strasbourg, France.; RESO : Centre de Référence des Maladies Autoimmunes Systémiques Rares Est Sud-Ouest, France; INSERM UMR_S1109, Université de Strasbourg, F-67000 Strasbourg, France. Electronic address:

To date, no immunomodulatory drug has proved efficacious in primary Sjögren's syndrome (pSS). In pSS, difficulties in drug efficacy assessment is related to the large spectrum of clinical involvements (glandular/extraglandular involvement), to the lack of correlation between symptoms of dryness and glandular function assessed by objective measurements, as well as between symptoms and systemic complications of the disease. Severe organ manifestations are generally treated by off-label therapies in accordance with current practice and guidelines for Systemic Lupus Erythematosus or other connective-tissue diseases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2018.12.008DOI Listing
April 2019
1 Read

Diagnosis of gluten-related disorders: A new and challenging public health problem.

Autoimmun Rev 2019 Apr 5. Epub 2019 Apr 5.

Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania; Emergency Hospital for Children, Cluj-Napoca, Romania. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2019.02.008DOI Listing
April 2019
7.933 Impact Factor

G-CSF-induced aortitis: Two cases and review of the literature.

Autoimmun Rev 2019 Apr 5. Epub 2019 Apr 5.

HHLH Center, Theme Cancer, Karolinska University Hospital, Stockholm, Sweden; Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden. Electronic address:

Background: Febrile neutropenia is generally recognised as a complication of myelosuppressive chemotherapy. Recombinant human granulocyte colony stimulating factor (G-CSF) is commonly used as a primary or secondary prophylaxis to reduce the degree and duration of neutropenia in patients at risk of developing chemotherapy-induced neutropenic fever and infectious complications. G-CSF is known to decrease mortality and increase the possibility of maintaining adequate chemotherapy dose intensity and density, which is essential in curable malignancies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2018.12.011DOI Listing
April 2019
1 Read

Emerging role of air pollution in autoimmune diseases.

Autoimmun Rev 2019 Apr 5. Epub 2019 Apr 5.

Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, 81 Meishan Road, Hefei, Anhui, China; Anhui Province Key Laboratory of Major Autoimmune Diseases, 81 Meishan Road, Hefei, Anhui, China. Electronic address:

Autoimmune diseases (ADs) are a broad spectrum of disorders featured by the body's immune responses being directed against its own tissues, resulting in prolonged inflammation and subsequent tissue damage. Recently, the exposure to ambient air pollution has been implicated in the occurrence and development of ADs. Mechanisms linking air pollution exposures and ADs mainly include systemic inflammation, increased oxidative stress, epigenetic modifications induced by exposures and immune response caused by airway damage. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2018.12.010DOI Listing
April 2019
1 Read

Anakinra in idiopathic recurrent pericarditis refractory to immunosuppressive therapy; a preliminary experience in seven patients.

Autoimmun Rev 2019 Apr 5. Epub 2019 Apr 5.

Rheumatology Unit, Sheba Medical Center, Ramat Gan, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Ramat Gan, Israel; Laboratory of the Mosaics of Autoimmunity, Saint Petersburg University, Saint Petersburg, Russian Federation; Department of Internal Medicine 'B', Sheba Medical Center, Ramat Gan, Israel. Electronic address:

Background: Approximately 5% of idiopathic recurrent pericarditis (IRP) patients are refractory or intolerant to NSAIDs, Colchicine and corticosteroids. The empiric treatment approach for these patients includes immunosuppression with Azathioprine (AZA) or immunomodulation with intravenous human immunoglobulin (IVIG). We assessed the efficacy and safety of long-term Anakinra treatment in refractory IRP patients after failure of prior immunosuppressive therapy and/or failure of IVIG. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2019.01.005DOI Listing
April 2019
2 Reads

Is there a possible correlation between antibodies against lipopolysaccharide, intestinal and blood-brain barrier proteins in IBD subjects?

Authors:
Aristo Vojdani

Autoimmun Rev 2019 Apr 5. Epub 2019 Apr 5.

Immunosciences Lab, Inc., 822 S. Robertson Blvd, Ste 312, Los Angeles, CA 90035, USA; Department of Preventive Medicine, Loma Linda University, Loma Linda, CA 92350, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2019.01.001DOI Listing

Systemic rheumatic diseases: From biological agents to small molecules.

Autoimmun Rev 2019 Apr 5. Epub 2019 Apr 5.

Rheumatology Unit, University of Messina, Messina, Italy.

The development of biologics and small oral molecules has recently changed the scenario of pharmacologic treatment of systemic rheumatic diseases and it has become a real revolution. These drugs have innovative mechanisms of action, based on the inhibition of specific molecular or cellular targets directly involved in disease pathogenesis. This new scenario has lead to a regular update of the management recommendations of several institututions, such as those for Rheumatoid Arthritis treatment that address the use of conventional and biologic therapies including TNFin (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab), abatacept, rituximab, IL-6 inhibitors (tocilizumab and sarilumab), biosimilars and small oral molecules (the JAK inhibitors tofacitinib and baricitinib). Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15689972193008
Publisher Site
http://dx.doi.org/10.1016/j.autrev.2018.12.009DOI Listing
April 2019
4 Reads

Does intravenous immunoglobulin therapy in Guillain-Barré syndrome patients interfere with serological Zika detection?

Autoimmun Rev 2019 Apr 5. Epub 2019 Apr 5.

Institut National de la Santé et de la Recherche Médicale, Centre de Recherche des Cordeliers, Equipe - Immunopathologie et Immunointervention Thérapeutique, Sorbonne Université, Paris F-75006, France; Université Paris Descartes, Sorbonne Paris Cité, Paris F-75006, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2019.01.004DOI Listing
April 2019
3 Reads

Autoimmune signatures for prediction and diagnosis of autoimmune diabetes in Kuwait.

Autoimmun Rev 2019 Apr 5. Epub 2019 Apr 5.

Medical Division, Dasman Diabetes Institute, Kuwait.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2019.02.009DOI Listing
April 2019
7.933 Impact Factor

Endothelial function features and properties of large vessel behavior in systemic autoimmune diseases: a cross-talk among cardiovascular disease risk factors.

Autoimmun Rev 2019 Apr 5. Epub 2019 Apr 5.

Division of Rheumatology, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, SP, Brazil. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2019.01.002DOI Listing

Corticosteroids and immunosuppressive agents for idiopathic recurrent pericarditis.

Autoimmun Rev 2019 Apr 5. Epub 2019 Apr 5.

Sorbonne Universités, UPMC Univ Paris 06, UMR 7211, and Inflammation-Immunopathology-Biotherapy Department (DHU i2B), F-75005 Paris, France; INSERM, UMR_S 959, F-75013 Paris, France; CNRS, FRE3632, F-75005 Paris, France; AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology, F-75013 Paris, France. Electronic address:

Recurrent pericarditis is a frequent and troublesome complication of acute pericarditis. Aspirin or non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine are the mainstay of therapy but few data is available on second-line treatment. We retrospectively analyzed 13 patients, 7 females (54%), median age 40 years, with a median of 4 (IQR 1-6) recurrences per patient despite a well conducted first-line treatment and a median follow-up of 59 months (IQR 38-70). Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15689972193009
Publisher Site
http://dx.doi.org/10.1016/j.autrev.2019.04.001DOI Listing
April 2019
2 Reads

Amplifying the concept of psoriatic arthritis: The role of autoimmunity in systemic psoriatic disease.

Autoimmun Rev 2019 Apr 5. Epub 2019 Apr 5.

Rheumatology, Allergology and Clinical Immunology, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.

Psoriatic arthritis (PsA) is a chronic inflammatory arthritis that may be present in near 30% of patients affected by psoriasis (PsO), clinically characterized by inflammation of periarticular (e.g., enthesis) and articular structures. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15689972193008
Publisher Site
http://dx.doi.org/10.1016/j.autrev.2018.11.007DOI Listing
April 2019
5 Reads

Extracellular vesicles in autoimmune vasculitis - Little dirts light the fire in blood vessels.

Autoimmun Rev 2019 Apr 5. Epub 2019 Apr 5.

Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Corporal Michael J. Crescenz VA Medical Center (Philadelphia), Philadelphia, PA 19104, USA. Electronic address:

Systemic vasculitis is diverse group of autoimmune disorders which are characterized by inflammation of blood vessel walls with deep aching and burning pain. Their underlying etiology and pathophysiology still remain poorly understood. Extracellular vesicles (EVs), including exosomes, microvesicles (MVs), and apoptotic bodies, are membrane vesicular structures that are released either during cell activation, or when cells undergo programmed cell death, including apoptosis, necroptosis, and pyroptosis. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15689972193008
Publisher Site
http://dx.doi.org/10.1016/j.autrev.2018.12.007DOI Listing
April 2019
9 Reads

Evidence of complement activation in the thrombotic small vessels of a patient with catastrophic antiphospholipid syndrome treated with eculizumab.

Autoimmun Rev 2019 May 4;18(5):561-563. Epub 2019 Mar 4.

Cardiac Surgery Unit, Department of Cardiac, Thoracic and Vascular Sciences, University Hospital of Padua, Via Giustiniani, 2, 35, 128 Padua, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2019.03.015DOI Listing
May 2019
2 Reads

Immunoglobulin G (IgG) anticardiolipin antibodies and recurrent cardiovascular events. A systematic review and Bayesian meta-regression analysis.

Autoimmun Rev 2019 May 4;18(5):519-525. Epub 2019 Mar 4.

Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.

Background: Anticardiolipin antibodies of the immunoglobulin G isotype (IgG aCL) have been suggested as risk factor for arterial and venous thrombosis. No conclusive data in patients with coronary artery disease (CAD) do exist. We investigate the risk of recurrent CAD according to the presence of IgG aCL. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2019.03.005DOI Listing
May 2019
3 Reads

The role of interleukin-13 in chronic inflammatory intestinal disorders.

Autoimmun Rev 2019 May 4;18(5):549-555. Epub 2019 Mar 4.

First Department of Internal Medicine, University of Pavia, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy. Electronic address:

Interleukin (IL)-13 is a cytokine playing a pivotal role in T helper (Th)2 immune response supposed to be implicated in some intestinal disorders. IL-13 is produced by Th2 cells, natural killer T cell, innate lymphoid cells and innate immune cells, which contribute to trigger and maintain a chronic idiopathic intestinal inflammation. In murine models IL-13 exerts pleiotropic functions, playing either pathogenic or protective roles according to the different experimental conditions. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15689972193006
Publisher Site
http://dx.doi.org/10.1016/j.autrev.2019.03.012DOI Listing
May 2019
6 Reads

The effect of non-TNF-targeted biologics on vascular dysfunction in rheumatoid arthritis: A systematic literature review.

Autoimmun Rev 2019 May 4;18(5):501-509. Epub 2019 Mar 4.

Internal Medicine Unit, Department of Medical Sciences, University of Ferrara, Ferrara, Italy.

Background: Rheumatoid arthritis (RA) is burdened by a significant increase in cardiovascular disease (CVD) risk. Amongst CVD risk factors, endothelial dysfunction and arterial stiffness represent powerful predictors of atherosclerosis and cardiovascular events in the general population and in RA patients.

Methods: A systematic review of the literature was performed to identify the available data on the effect of non-TNF-targeted biologics licensed for the treatment of RA on endothelial function, arterial stiffness or subclinical atherosclerosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2019.03.008DOI Listing

Composite breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) and extra-nodal marginal zone lymphoma (MZL) in the capsule of a silicone breast implant.

Autoimmun Rev 2019 May 4;18(5):556-557. Epub 2019 Mar 4.

The Institute of Oncology and Hematology, Technion- Israel Institute of Technology, Haifa, Israel; Lady Davis Carmel Medical Center, Bruce and Ruth Rappaport Faculty of Medicine, Technion- Israel Institute of Technology, Haifa, Israel.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2019.03.014DOI Listing

Induction and maintenance treatment of inflammatory bowel disease: A comprehensive review.

Autoimmun Rev 2019 May 4;18(5):439-454. Epub 2019 Mar 4.

Department of Pediatrics, Yonsei University College of Medicine, Seoul, Republic of Korea. Electronic address:

Ulcerative colitis (UC) and Crohn's disease (CD) are the two major types of inflammatory bowel disease (IBD). We conducted a comprehensive review of meta-analyses to summarize the reported effectiveness of different drugs for IBD. We performed a literature search and a total of 110 meta-analyses from 66 articles were summarized and re-analyzed (62 in UC and 48 in CD). Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15689972193005
Publisher Site
http://dx.doi.org/10.1016/j.autrev.2019.03.002DOI Listing
May 2019
11 Reads

Efficacy and safety of rituximab for relapsing-remitting multiple sclerosis: A systematic review and meta-analysis.

Autoimmun Rev 2019 May 4;18(5):542-548. Epub 2019 Mar 4.

Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China. Electronic address:

Objective: To evaluate the efficacy and safety of rituximab for relapsing-remitting multiple sclerosis.

Results: Fifteen studies that collectively included 946 patients were selected for the meta-analysis. Rituximab therapy was associated with the mean annualized relapse rates decreasing by 0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2019.03.011DOI Listing
May 2019
1 Read

Influence of HLA-DRB1 susceptibility alleles on the autoantibodies spectrum of systemic lupus erythematosus in European part of Russia.

Autoimmun Rev 2019 May 4;18(5):558-560. Epub 2019 Mar 4.

Laboratory of the Mosaics of Autoimmunity, Saint-Petersburg University, Saint Petersburg, Russia; Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Israel; Sackler Faculty in Medicine, Sheba Medical Center, Tel-Aviv University, Israel.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2019.03.013DOI Listing

Serum and blister fluid levels of cytokines and chemokines in pemphigus and bullous pemphigoid.

Autoimmun Rev 2019 May 4;18(5):526-534. Epub 2019 Mar 4.

Department of Dermatology, University of Illinois at Chicago, USA. Electronic address:

Bullous pemphigoid and pemphigus constitute two major autoimmune blistering diseases (AIBD) with complicated disease pathomechanisms involving a multitude of cytokines and immunological pathways. The purpose of our literature review of the cytokines and chemokines involved in these AIBDs was to allow for a meta-analysis of studies detailing differential cytokine and chemokine changes in these conditions. Elucidation of inflammatory pathways could lead to more targeted therapies, several of which specific monoclonal antibodies already exist and are used safely for other autoimmune diseases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2019.03.009DOI Listing

Immunoglobulin replacement for secondary immunodeficiency after B-cell targeted therapies in autoimmune rheumatic disease: Systematic literature review.

Autoimmun Rev 2019 May 4;18(5):535-541. Epub 2019 Mar 4.

Frimley Health NHS Foundation Trust, Portsmouth Rd, Frimley, UK. Electronic address:

Background: Consensus guidelines are not available for the use of immunoglobulin replacement therapy (IGRT) in patients developing iatrogenic secondary antibody deficiency following B-cell targeted therapy (BCTT) in autoimmune rheumatic disease.

Objectives: To evaluate the role of IGRT to manage hypogammaglobulinemia following BCTT in autoimmune rheumatic disease (AIRD).

Methods: Using an agreed search string we performed a systematic literature search on Medline with Pubmed as vendor. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2019.03.010DOI Listing
May 2019
1 Read
7.933 Impact Factor

Juvenile temporal arteritis: A clinicopathological multicentric experience.

Autoimmun Rev 2019 May 4;18(5):476-483. Epub 2019 Mar 4.

Department of internal medicine, Hôtel-Dieu, CHU Nantes, Nantes, France. Electronic address:

Introduction: Juvenile temporal arteritis (JTA) is a recently-described and little-known inflammatory disease and its etiology is undetermined. Less than forty cases have been published. This paper is aimed at reporting the largest JTA series and to compare it to literature data to better evaluate its characteristics at diagnosis, its evolution and treatment options. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15689972193006
Publisher Site
http://dx.doi.org/10.1016/j.autrev.2019.03.007DOI Listing
May 2019
8 Reads

Ocular involvement in granulomatosis with polyangiitis: A single-center cohort study on 63 patients.

Autoimmun Rev 2019 May 4;18(5):493-500. Epub 2019 Mar 4.

National Referral Center for Rare Systemic Autoimmune Diseases, Department of Internal Medicine, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Paris, France. Electronic address:

Objective: To analyse the ocular manifestations of patients with GPA, their treatment and outcome.

Methods: Retrospective cohort study performed at the National Referral Center for Vasculitis, Cochin Hospital, Paris (France), from January 2005 to December 2015. Among 308 patients with a new diagnosis of GPA in accordance with the American College of Rheumatology classification criteria and/or revised Chapel Hill nomenclature definitions, we identified those with ocular involvement and a subsequent follow up in our center. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15689972193005
Publisher Site
http://dx.doi.org/10.1016/j.autrev.2019.03.001DOI Listing
May 2019
7 Reads

Microbe-metabolite-host axis, two-way action in the pathogenesis and treatment of human autoimmunity.

Autoimmun Rev 2019 May 4;18(5):455-475. Epub 2019 Mar 4.

Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei, Anhui, China; Anhui Province Key Laboratory of Major Autoimmune Diseases, 81 Meishan Road, Hefei, Anhui, China. Electronic address:

The role of microorganism in human diseases cannot be ignored. These microorganisms have evolved together with humans and worked together with body's mechanism to maintain immune and metabolic function. Emerging evidence shows that gut microbe and their metabolites open up new doors for the study of human response mechanism. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2019.03.006DOI Listing
May 2019
2 Reads

Refractory lupus nephritis: When, why and how to treat.

Autoimmun Rev 2019 May 4;18(5):510-518. Epub 2019 Mar 4.

Vasculitis and Lupus Clinic, Addenbrooke's Hospital, Hills Road, CB2 0QQ, Cambridge, Cambridge University Hospitals, United Kingdom; Department of Medicine, University of Cambridge, CB2 0QQ Cambridge, United Kingdom. Electronic address:

Refractory lupus nephritis indicates an inadequate response to lupus nephritis therapy. It implies persisting or worsening disease activity despite therapy, but the definition is complicated by the parameters of response, proteinuria and renal function, that do not discriminate clearly between activity and irreversible damage. Understanding the causes of refractory disease and developing treatment strategies is important because these patients are more likely to develop poor outcomes, especially end stage renal disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2019.03.004DOI Listing
May 2019
1 Read

Free light chains and autoimmunity.

Autoimmun Rev 2019 May 4;18(5):484-492. Epub 2019 Mar 4.

Area Diagnostica di Laboratorio, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.

The study of free light chains (FLCs) has grown as area of enormous interest for many clinicians with the aim of disclosing the exact biological role and potential use of FLCs in the clinical routine. Moreover, the attention given to immunological functions of FLCs has sparked a new light into their pathogenic contribution in different chronic autoimmune-based inflammatory diseases. The release of intracellular antigens following cell death or ineffective clearance of apoptotic debris, modification of self-antigens, and molecular mimicry may trigger the production of immunoglobulins after activation and polyclonal expansion of B cells, by which FLCs are released. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15689972193005
Publisher Site
http://dx.doi.org/10.1016/j.autrev.2019.03.003DOI Listing
May 2019
9 Reads

CD8+ cells as a predominant biomarker for inclusion body myositis.

Autoimmun Rev 2019 Apr 28;18(4):325-333. Epub 2019 Feb 28.

Centre of Research in Myology, Sorbonne Université, INSERM, Association Institut de Myologie, UMRS 974, 75013 Paris, France; Department of Internal Medicine and Clinical Immunology, Pitié-Salpêtrière University Hospital, DHU I2B, AP-HP, INSERM, UMR 974, 75103 Paris, France.

Background: Myositis is a heterogeneous group of muscular auto-immune diseases with clinical and pathological criteria that allow the classification of patients into different sub-groups. Inclusion body myositis is the most frequent myositis above fifty years of age. Diagnosing inclusion body myositis requires expertise and is challenging. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15689972193002
Publisher Site
http://dx.doi.org/10.1016/j.autrev.2019.02.003DOI Listing
April 2019
12 Reads

Amino acid metabolism as drug target in autoimmune diseases.

Autoimmun Rev 2019 Apr 22;18(4):334-348. Epub 2019 Feb 22.

Department of Experimental Medicine, University of Perugia, 06132 Perugia, Italy. Electronic address:

In mammals, amino acid metabolism has evolved to control immune responses. Autoimmune diseases are heterogeneous conditions that involve the breakdown of tolerogenic circuitries and consequent activation of autoreactive immune cells. Therefore, critical enzymes along amino acid degradative pathways may be hijacked to keep in check autoimmunity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2019.02.004DOI Listing

The study of interactions between genome and exposome in the development of systemic lupus erythematosus.

Autoimmun Rev 2019 Apr 14;18(4):382-392. Epub 2019 Feb 14.

Copenhagen Lupus and Vasculitis Clinic, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark; Department of Clinical Medicine, Faculty of Health Science, University of Copenhagen, Denmark.. Electronic address:

Systemic lupus erythematosus (SLE) is a systemic inflammatory autoimmune disease characterized by a broad spectrum of clinical and serological manifestations. This may reflect a complex and multifactorial etiology involving several identified genetic and environmental factors, though not explaining the full risk of SLE. Established SLE risk genotypes are either very rare or with modest effect sizes and twin studies indicate that other factors besides genetics must be operative in SLE etiology. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2018.11.005DOI Listing
April 2019
3 Reads

Juvenile polyautoimmunity in a rheumatology setting.

Autoimmun Rev 2019 Apr 14;18(4):369-381. Epub 2019 Feb 14.

Center for Autoimmune Diseases Research (CREA), School of Medicine and Health Sciences, Universidad del Rosario, Bogota, Colombia.. Electronic address:

Overt polyautoimmunity (PolyA) corresponds to the presence of more than one well-defined autoimmune disease (AD) manifested clinically in a single patient. The current study aimed to describe the main characteristics of juvenile PolyA in a pediatric rheumatology setting and analyze the chronological aspects, index cases, familial autoimmunity, and clustering pattern. This was a cross-sectional and multicenter study in which 313 children with overt PolyA were included. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2018.11.006DOI Listing
April 2019
2 Reads
7.933 Impact Factor

The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): A survey of 1000 consecutive cases.

Autoimmun Rev 2019 Apr 15;18(4):406-414. Epub 2019 Feb 15.

Obstetrics and Gynaecology Department, High Risk Unit, Vall d'Hebron University Hospital, Universitat Autonoma, Barcelona, Spain.

Aim: To analyse the clinical features, laboratory data and foetal-maternal outcomes, and follow them up on a cohort of 1000 women with obstetric antiphospholipid syndrome (OAPS).

Methods: The European Registry of OAPS became a registry within the framework of the European Forum on Antiphospholipid Antibody projects and was placed on a website in June 2010. Thirty hospitals throughout Europe have collaborated to carry out this registry. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2018.12.006DOI Listing
April 2019
1 Read

Enhanced type I interferon gene signature in primary antiphospholipid syndrome: Association with earlier disease onset and preeclampsia.

Autoimmun Rev 2019 Apr 14;18(4):393-398. Epub 2019 Feb 14.

Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo (USP), Brazil.

Objective: Recently, two studies demonstrated that a relevant percentage of primary antiphospholipid syndrome (PAPS) patients had an upregulation of interferon (IFN) genes. However, 20%-28% of these patients had anti-dsDNA, a highly specific systemic lupus erythematosus (SLE) autoantibody. This study aimed to determine the prevalence of the type I IFN signature in the peripheral blood mononuclear cells of PAPS patients without specific SLE autoantibodies and search for its clinical associations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2018.11.004DOI Listing
April 2019
2 Reads

Lethal immunoglobulins: Autoantibodies and sudden cardiac death.

Autoimmun Rev 2019 Apr 14;18(4):415-425. Epub 2019 Feb 14.

Laboratory of the Mosaics of Autoimmunity, Saint Petersburg State University, Saint-Petersburg, Russian Federation; Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Affiliated to Tel-Aviv University School of Medicine, Tel-Hashomer, Israel.

Sudden cardiac death (SCD) is an unexpected death due to cardiac causes that occurs in a short time period (generally within 1 h of symptom onset) in a person with known or unknown cardiac disease. Patients with cardiomyopathies, myocarditis, ischemic heart disease and cardiac channelopathies are at risk of SCD. However, a certain percentage of autopsy-negative cases of SCD in the young (<35 years) remain unexplained even after a post-mortem genetic testing. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2018.12.005DOI Listing
April 2019
11 Reads

Blood-brain barrier disruption and neuroinflammation as pathophysiological mechanisms of the diffuse manifestations of neuropsychiatric systemic lupus erythematosus.

Autoimmun Rev 2019 Apr 11;18(4):426-432. Epub 2019 Feb 11.

Universidad de Antioquia, Facultad de Medicina, Grupo de Inmunología Celular e Inmunogenética-GICIG, Medellín, Colombia.

Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease that can involve nervous system commitment known as neuropsychiatric systemic lupus erythematosus (NPSLE). The diagnostic of NPSLE is complex because the symptoms range from focal symptoms (e.g. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2018.12.004DOI Listing
April 2019
1 Read

Conceptual, statistical and clinical interpretation of results from a systematic review and meta-analysis of prevalence of cervical HPV infection in women with SLE.

Autoimmun Rev 2019 Apr 11;18(4):433-434. Epub 2019 Feb 11.

The University of Adelaide, North Terrace Campus, Adelaide, South Australia 5005, Australia.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15689972193003
Publisher Site
http://dx.doi.org/10.1016/j.autrev.2018.12.003DOI Listing
April 2019
7 Reads

Reply to the editor.

Autoimmun Rev 2019 Apr 10;18(4):435-436. Epub 2019 Feb 10.

Department of Autoimmune Diseases, Hospital Clinic, Barcelona, Catalonia, Spain. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15689972193003
Publisher Site
http://dx.doi.org/10.1016/j.autrev.2019.02.007DOI Listing
April 2019
9 Reads

Rituximab therapy for primary central nervous system vasculitis: A 6 patient experience and review of the literature.

Autoimmun Rev 2019 Apr 10;18(4):399-405. Epub 2019 Feb 10.

Division of Rheumatology, Mayo Clinic, Rochester, MN, United States.

Objectives: To assess the efficacy and safety of Rituximab (RTX) in adult primary central nervous system vasculitis (PCNSV).

Methods: We retrospectively assessed the effect of RTX in 6 patients with PCNSV. Five of the 6 were refractory to high dose glucocorticoids (GCs) and/or conventional immunosuppressants (IS). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2018.12.002DOI Listing
April 2019
2 Reads

Microvascular heart involvement in systemic autoimmune diseases: The purinergic pathway and therapeutic insights from the biology of the diseases.

Autoimmun Rev 2019 Apr 7;18(4):317-324. Epub 2019 Feb 7.

Institute of Rheumatology, Catholic University of the Sacred Heart, Fondazione Policlinico Universitario A. Gemelli - Presidio Columbus, Rome, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2019.02.002DOI Listing
April 2019
3 Reads

Pemphigus and mucous membrane pemphigoid: An update from diagnosis to therapy.

Autoimmun Rev 2019 Apr 7;18(4):349-358. Epub 2019 Feb 7.

Department of Biomedical Sciences and Human Oncology, Unit of Internal Medicine "Guido Baccelli", University of Bari Medical School, Bari, Italy. Electronic address:

Pemphigus diseases (PDs) and mucous membrane pemphigoid (MMP) are a group of immune-mediated mucocutaneous disorders clinically characterized by the formation of blisters, erosions and ulcers. The skin and mucous membranes are predominantly affected, with the oropharyngeal mucosa as the initially involved site. Ocular involvement is also a frequent feature of these diseases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2019.02.005DOI Listing
April 2019
19 Reads

Immune checkpoints and the regulation of tolerogenicity in dendritic cells: Implications for autoimmunity and immunotherapy.

Autoimmun Rev 2019 Apr 8;18(4):359-368. Epub 2019 Feb 8.

Millennium Institute on Immunology and Immunotherapy, Departamento de Genética Molecular y Microbiología, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile; Departamento de Endocrinología, Escuela de Medicina, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile. Electronic address:

The immune system is responsible for defending the host from a large variety of potential pathogens, while simultaneously avoiding immune reactivity towards self-components. Self-tolerance has to be tightly maintained throughout several central and peripheral processes; immune checkpoints are imperative for regulating the immunity/tolerance balance. Dendritic cells (DCs) are specialized cells that capture antigens, and either activate or inhibit antigen-specific T cells. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15689972193003
Publisher Site
http://dx.doi.org/10.1016/j.autrev.2019.02.006DOI Listing
April 2019
18 Reads

A review of the evidence for a natalizumab exit strategy for patients with multiple sclerosis.

Autoimmun Rev 2019 Mar 11;18(3):255-261. Epub 2019 Jan 11.

Department of Neurology, Medical University of Vienna, Vienna, Austria.

Natalizumab is an effective treatment for relapsing-remitting multiple sclerosis (RRMS), but treatment for >2 years is associated with an increased risk of opportunistic infection and progressive multifocal leukoencephalopathy (PML). For this reason, patients and physicians may consider discontinuing natalizumab therapy. This article reviews the evidence for the various therapeutic approaches that may be taken in such patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2018.09.012DOI Listing
March 2019
4 Reads

Complex regional pain syndrome - False hopes and miscommunications.

Autoimmun Rev 2019 Mar 11;18(3):270-278. Epub 2019 Jan 11.

Division of Rheumatology, Allergy and Clinical Immunology, University of California at Davis School of Medicine, United States. Electronic address:

Complex regional pain syndrome (CRPS) has been considered to be an autoimmune disease and there have been clinical trials with intravenous immunoglobulin. Often the etiology of the so-called CRPS diagnosis cannot be discerned and there are no validated instruments that provide functional metrics. The term complex regional pain syndrome (CRPS), coined in 1994 to describe patients in whom the pain is out of proportion to the injury, was actually a diagnosis proposed during the American Civil War, but was originally known as causalgia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2018.10.003DOI Listing
March 2019
15 Reads

Myositis-specific autoantibodies, a cornerstone in immune-mediated necrotizing myopathy.

Autoimmun Rev 2019 Mar 11;18(3):223-230. Epub 2019 Jan 11.

Department of Internal Medicine and Clinical Immunology, Sorbonne Université, Pitié-Salpêtrière University Hospital, Paris, France; Institut National de la Santé et de la Recherche Médicale, Association Institut de Myologie, Centre de Recherche en Myologie, UMRS974, Paris, France. Electronic address:

Over the past few years, myositis-specific autoantibodies played an increasing role in the inflammatory idiopathic myositis definition. They became the critical immunological marker for immune-mediated necrotizing myopathy diagnosis (IMNM) since the paradigm switch from histological to serological criteria. This review is focused on the key role of the anti-signal recognition particle (anti-SRP) and the anti-3-Hydroxy-3-MethylGlutaryl-Coenzyme A Reductase (anti-HMGCR) antibodies in immune-mediated necrotizing myopathy. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15689972193000
Publisher Site
http://dx.doi.org/10.1016/j.autrev.2018.09.008DOI Listing
March 2019
23 Reads

Mechanisms of action and historical facts on the use of intravenous immunoglobulins in systemic lupus erythematosus.

Autoimmun Rev 2019 Mar 11;18(3):279-286. Epub 2019 Jan 11.

GIRAT: Grupo de Investigación en Reumatología, Autoinmunidad y Medicina traslacional. Fundación Valle del Lili, Univesidad Icesi, Colombia; Laboratory of immunology, Fundación Valle del Lili, Cali, Colombia. Electronic address:

The current existing therapies for severe cases of systemic lupus erythematosus (SLE) patients are still limited. Intravenous immunoglobulin (IVIGs), which are purified from the plasma of thousands of healthy human donors, have been profiled as efficacious and life-saving options for SLE patients refractory to conventional therapy. The specific mechanism of action by which IVIGs generate immunomodulation in SLE is not currently understood. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2018.10.002DOI Listing
March 2019
5 Reads

Effectiveness and safety of rituximab for the treatment of refractory systemic sclerosis associated calcinosis: A case series and systematic review of the literature.

Autoimmun Rev 2019 Mar 11;18(3):262-269. Epub 2019 Jan 11.

Department of Clinical Immunology and Rheumatology, Pontificia Universidad Católica de Chile, Chile.

Objective: To analyze the effectiveness and safety of rituximab (RTX) for the treatment of refractory systemic sclerosis (SSc)-associated calcinosis.

Methods: We undertook an observational study of patients with this complication treated with 1 or more cycles of RTX (1 g × 2 weeks) and evaluated for at least 12 months after RTX treatment in a single center. The primary outcome measures of the study were the improvement of calcinosis symptoms (pain, signs of local inflammation, and new episodes of skin ulceration) and the radiologic evolution of the calcification(s). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2018.10.006DOI Listing
March 2019
5 Reads

The association of other autoimmune diseases in patients with Graves' disease (with or without ophthalmopathy): Review of the literature and report of a large series.

Autoimmun Rev 2019 Mar 11;18(3):287-292. Epub 2019 Jan 11.

Department of Clinical and Experimental Medicine, University of Pisa, Via Savi 10, Pisa 56126, Italy. Electronic address:

Graves' disease (GD) and autoimmune thyroiditis (AT) are the two main clinical presentations of AITD, and their clinical hallmarks are thyrotoxicosis and hypothyroidism, respectively. GD, and AT, can be associated with other organ specific, or systemic autoimmune diseases in the same patient. However discordant results have been reported in the literature about the possible associations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2018.10.001DOI Listing
March 2019
18 Reads